Decreased maternal and fetal cholesterol following maternal bococizumab (anti-PCSK9 monoclonal antibody) administration does not affect rat embryo-fetal development

Regulatory Toxicology and Pharmacology

Volumn 73, Issue 2, 2015, Pages 562-570

  Campion, Sarah N ^a   Han, Bora ^a   Cappon, Gregg D ^a   Lewis, Elise M ^b   Kraynov, Eugenia ^a   Liang, Hong ^a   Bowman, Christopher J ^a  

^a PFIZER INC   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

Bococizumab; Cholesterol; Embryo fetal development; Monoclonal antibody

Indexed keywords

BOCOCIZUMAB; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, RAT; SERINE PROTEINASE;

ADVERSE DRUG REACTION; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; EMBRYO DEVELOPMENT; FEMALE; FETUS; FETUS DEVELOPMENT; NONHUMAN; ORGANOGENESIS; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; ANIMAL; BLOOD; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; FETOMATERNAL TRANSFUSION; PHYSIOLOGY; PREGNANCY; PRENATAL EXPOSURE; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FETAL DEVELOPMENT; MATERNAL-FETAL EXCHANGE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RATS, SPRAGUE-DAWLEY; SERINE ENDOPEPTIDASES;

EID: 84982161565     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2015.08.007     Document Type: Article

References (52)

1. Amundsen A.L., Khoury J., Iversen P.O., Bergei C., Ose L., Tonstad S., Retterstol K. Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. Atherosclerosis 2006, 189(2):451-457.
2. Avis H.J., Hutten B.A., Twickler M.T., Kastelein J.J., van der Post J.A., Stalenhoef A.F., Vissers M.N. Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn?. Curr. Opin. Lipidol. 2009, 20(6):484-490.
3. Baardman M.E., Erwich J.J., Berger R.M., Hofstra R.M., Kerstjens-Frederikse W.S., Lutjohann D., Plosch T. The origin of fetal sterols in second-trimester amniotic fluid: endogenous synthesis or maternal-fetal transport?. Am. J. Obstet. Gynecol. 2012, 207(3):202. e219-225.
4. Baardman M.E., Kerstjens-Frederikse W.S., Berger R.M., Bakker M.K., Hofstra R.M., Plosch T. The role of maternal-fetal cholesterol transport in early fetal life: current insights. Biol. Reprod. 2013, 88(1):24.
5. Belknap W.M., Dietschy J.M. Sterol synthesis and low density lipoprotein clearance in vivo in the pregnant rat, placenta, and fetus. Sources for tissue cholesterol during fetal development. J. Clin. Investig. 1988, 82(6):2077-2085.
6. Bosch V., Camejo G. Serum lipoproteinemia in pregnant and lactating rats. J. Lipid Res. 1967, 8(2):138-141.
7. Bowman C.J., King L.E., Stedman D.B. Embryo-fetal distribution of a biopharmaceutical IgG2 during rat organogenesis. Reprod. Toxicol. 2012, 34(1):66-72.
8. 125iodinated humanized immunoglobulin G2δa in the cynomolgus monkey. Reprod. Toxicol. 2014, 48(30).
9. Chiang A.N., Yang M.L., Hung J.H., Chou P., Shyn S.K., Ng H.T. Alterations of serum lipid levels and their biological relevances during and after pregnancy. Life Sci. 1995, 56(26):2367-2375.
10. Coder P.S., Thomas J.A., Stedman D.B., Bowman C.J. Placental transfer of (125)Iodinated humanized immunoglobulin G2Deltaa in the Sprague Dawley rat. Reprod. Toxicol. 2013, 38:37-46.
11. DeSesso J.M., Williams A.L., Ahuja A., Bowman C.J., Hurtt M.E. The placenta, transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy. Crit. Rev. Toxicol. 2012, 42(3):185-210.
12. Dostal L.A., Schardein J.L., Anderson J.A. Developmental toxicity of the HMG-CoA reductase inhibitor, atorvastatin, in rats and rabbits. Teratology 1994, 50(6):387-394.
13. Dunn O.J. Multiple contrasts using rank sums. Technometrics 1964, 6:241-252.
14. Dunnett C.W. A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 1955, 50:1096-1121.
15. Grozdanov P.N., Petkov P.M., Karagyozov L.K., Dabeva M.D. Expression and localization of PCSK9 in rat hepatic cells. Biochem. Cell Biol. 2006, 84(1):80-92.
16. Gumbiner B., Udata C., Joh T., Liang H., Wan H., Shelton D., Forgues P., Billotte S., Pons J., Baum C.M., Garzone P.D. The effects of single dose administration of RN316 (PF-04950615), a humanized IgG2a monoclonal antibody binding proprotein convertase subtilisin kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin (abstract). Circulation 2012, 126(21).
17. Jurevics H.A., Kidwai F.Z., Morell P. Sources of cholesterol during development of the rat fetus and fetal organs. J. Lipid Res. 1997, 38(4):723-733.
18. Kusters D.M., Hassani Lahsinoui H., van de Post J.A., Wiegman A., Wijburg F.A., Kastelein J.J., Hutten B.A. Statin use during pregnancy: a systematic review and meta-analysis. Expert Rev. Cardiovasc. Ther. 2012, 10(3):363-378.
19. Lankas G.R., Cukierski M.A., Wise L.D. The role of maternal toxicity in lovastatin-induced developmental toxicity. Birth Defects Res. B Dev. Reprod. Toxicol. 2004, 71(3):111-123.
20. Malek A., Sager R., Kuhn P., Nicolaides K.H., Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am. J. Reprod. Immunol. 1996, 36(5):248-255.
21. Martin D.E., Wolf R.C., Meyer R.K. Plasma lipid levels during pregnancy in the rhesus monkey (Macaca mulatta). Proc. Soc. Exp. Biol. Med. 1971, 138(2):638-641.
22. Martin P.L., Weinbauer G.F. Developmental toxicity testing of biopharmaceuticals in nonhuman primates: previous experience and future directions. Int. J. Toxicol. 2010, 29(6):552-568.
23. Martin U., Davies C., Hayavi S., Hartland A., Dunne F. Is normal pregnancy atherogenic?. Clin. Sci. Lond. 1999, 96(4):421-425.
24. Minsker D.H., MacDonald J.S., Robertson R.T., Bokelman D.L. Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase. Teratology 1983, 28(3):449-456.
25. Moffat G.J., Retter M.W., Kwon G., Loomis M., Hock M.B., Hall C., Bussiere J., Lewis E.M., Chellman G.J. Placental transfer of a fully human IgG2 monoclonal antibody in the cynomolgus monkey, rat, and rabbit: a comparative assessment from during organogenesis to late gestation. Birth Defects Res. B Dev. Reprod. Toxicol. 2014, 101(2):178-188.
26. Mousavi S.A., Berge K.E., Leren T.P. The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis. J. Intern. Med. 2009, 266(6):507-519.
27. Napoli C., de Nigris F., Welch J.S., Calara F.B., Stuart R.O., Glass C.K., Palinski W. Maternal hypercholesterolemia during pregnancy promotes early atherogenesis in LDL receptor-deficient mice and alters aortic gene expression determined by microarray. Circulation 2002, 105(11):1360-1367.
28. Napoli C., Glass C.K., Witztum J.L., Deutsch R., D'Armiento F.P., Palinski W. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet 1999, 354(9186):1234-1241.
29. Palinski W., D'Armiento F.P., Witztum J.L., de Nigris F., Casanada F., Condorelli M., Silvestre M., Napoli C. Maternal hypercholesterolemia and treatment during pregnancy influence the long-term progression of atherosclerosis in offspring of rabbits. Circ. Res. 2001, 89(11):991-996.
30. Siegel S. The Fisher's Exact Probability Test. Nonparametric Statistics for the Behavioral Sciences 1956, 96-105. McGraw-Hill Co, New York, NY.
31. Simister N.E. Placental transport of immunoglobulin G. Vaccine 2003, 21(24):3365-3369.
32. Simister N.E., Story C.M. Human placental Fc receptors and the transmission of antibodies from mother to fetus. J. Reprod. Immunol. 1997, 37(1):1-23.
33. Smith J.L., Lear S.R., Forte T.M., Ko W., Massimi M., Erickson S.K. Effect of pregnancy and lactation on lipoprotein and cholesterol metabolism in the rat. J. Lipid Res. 1998, 39(11):2237-2249.
34. Snedecor G.W., Cochran W.G. Analysis of Variance. Statistical Methods 1967, 258-298. Iowa State University Press, Ames.
35. Snedecor G.W., Cochran W.G. Variance Test for Homogeneity of the Binomial Distribution. Statistical Methods 1967, 240-241. Iowa State University Press, Ames.
36. Sokal R.R., Rohlf F.J. Bartlett's Test of Homogeneity of Variances. Biometry: the Principles and Practice of Statistics in Biological Research 1969, 370-371. Freeman & Co, San Francisco, CA.
37. Sokal R.R., Rohlf F.J. Kruskal-Wallis Test. Biometry: the Principles and Practice of Statistics in Biological Research 1969, 388-391. Freeman & Co, San Francisco, CA.
38. Staples R.E. Detection of visceral alterations in mammalian fetuses. Teratology 1974, 9(3):A37-A38.
39. Staples R.E., Schnell V.L. Refinements in rapid clearing technic in the Koh-Alizarin red S method for fetal bone. Stain Technol. 1964, 39:61-63.
40. Tanase H., Asai M., Hirose K. Reproduction study of pravastatin sodium administered during the period of fetal organogenesis in rabbits. Jpn. Pharmacol. Ther. 1987, 15(12):67-73.
41. Tanase H., Hirose K. Reproduction study of pravastatin sodium administered during the period of fetal organogenesis in rats. Jpn. Pharmacol. Ther. 1987, 15(12):45-56.
42. Thorn M., Piche-Nicholas N., Stedman D., Davenport S.W., Zhang N., Collinge M., Bowman C.J. Embryo-fetal transfer of bevacizumab (Avastin) in the rat over the course of gestation and the impact of neonatal Fc receptor (FcRn) binding. Birth Defects Res. B Dev. Reprod. Toxicol. 2012, 95(5):363-375.
43. Tint G.S., Yu H., Shang Q., Xu G., Patel S.B. The use of the Dhcr7 knockout mouse to accurately determine the origin of fetal sterols. J. Lipid Res. 2006, 47(7):1535-1541.
44. van der Graaf A., Vissers M.N., Gaudet D., Brisson D., Sivapalaratnam S., Roseboom T.J., Jansen A.C., Kastelein J.J., Hutten B.A. Dyslipidemia of mothers with familial hypercholesterolemia deteriorates lipids in adult offspring. Arterioscler. Thromb. Vasc. Biol. 2010, 30(12):2673-2677.
45. Weinreich M., Frishman W.H. Antihyperlipidemic therapies targeting PCSK9. Cardiol. Rev. 2014, 22(3):140-146.
46. Wilson J.G. Methods for administering agents and detecting malformations in experimental animals. Teratology: Principles and Techniques 1965, 262-277. University of Chicago Press, Chicago, IL. J.G. Wilson, J. Warkany (Eds.).
47. Wise L.D., Majka J.A., Robertson R.T., Bokelman D.L., Nakatsuka T., Akutsu S., Fujii T. Simvastatin (MK-0733): oral teratogenicity study in rats. Pre- and postnatal observations. Jpn. Pharmacol. Ther. 1990, 39(2):143-158.
48. Wise L.D., Prahalada S., Robertson R.T., Bokelman D.L., Akutsu S., Fujii T. Simvastatin (MK-0733): oral teratogenicity study in rabbits. Jpn. Pharmacol. Ther. 1990, 39(2):159-167.
49. Woollett L.A. Origin of cholesterol in the fetal golden Syrian hamster: contribution of de novo sterol synthesis and maternal-derived lipoprotein cholesterol. J. Lipid Res. 1996, 37(6):1246-1257.
50. Woollett L.A. Maternal cholesterol in fetal development: transport of cholesterol from the maternal to the fetal circulation. Am. J. Clin. Nutr. 2005, 82(6):1155-1161.
51. Woollett L.A. Where does fetal and embryonic cholesterol originate and what does it do?. Annu. Rev. Nutr. 2008, 28:97-114.
52. Zilversmit D.B., Hughes L.B., Remington M. Hypolipidemic effect of pregnancy in the rabbit. J. Lipid Res. 1972, 13(6):750-756.